Brokerages Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) PT at $87.80

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have received an average rating of “Moderate Buy” from the twelve ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $87.80.

Several brokerages recently weighed in on ARWR. Weiss Ratings cut Arrowhead Pharmaceuticals from a “hold (c-)” rating to a “sell (d-)” rating in a report on Wednesday, May 20th. HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Arrowhead Pharmaceuticals in a report on Wednesday, March 25th. Wall Street Zen cut Arrowhead Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. Sanford C. Bernstein increased their price objective on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. Finally, Morgan Stanley upgraded Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $78.00 to $100.00 in a report on Tuesday, April 21st.

Insiders Place Their Bets

In other Arrowhead Pharmaceuticals news, Director Hongbo Lu sold 2,970 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total value of $228,333.60. Following the completion of the sale, the director owned 52,012 shares in the company, valued at approximately $3,998,682.56. This trade represents a 5.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider James C. Hamilton sold 10,000 shares of the stock in a transaction that occurred on Thursday, April 23rd. The stock was sold at an average price of $75.00, for a total value of $750,000.00. Following the completion of the sale, the insider owned 226,958 shares of the company’s stock, valued at approximately $17,021,850. This trade represents a 4.22% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 36,065 shares of company stock worth $2,554,562. 3.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Tsfg LLC bought a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter worth approximately $25,000. iSAM Funds UK Ltd bought a new position in shares of Arrowhead Pharmaceuticals in the 3rd quarter worth approximately $29,000. First Horizon Corp bought a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter worth approximately $32,000. WPG Advisers LLC grew its position in shares of Arrowhead Pharmaceuticals by 384.8% in the 4th quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock worth $36,000 after buying an additional 431 shares during the period. Finally, Hantz Financial Services Inc. grew its position in shares of Arrowhead Pharmaceuticals by 177.1% in the 4th quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company’s stock worth $49,000 after buying an additional 471 shares during the period. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Trading Down 1.4%

Shares of ARWR stock opened at $77.91 on Tuesday. The stock has a market capitalization of $10.97 billion, a PE ratio of -36.24 and a beta of 1.28. Arrowhead Pharmaceuticals has a 1-year low of $14.30 and a 1-year high of $82.26. The business has a 50-day moving average of $69.56 and a 200 day moving average of $64.39. The company has a debt-to-equity ratio of 1.41, a current ratio of 6.23 and a quick ratio of 6.23.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.17. The company had revenue of $73.74 million during the quarter, compared to analysts’ expectations of $73.84 million. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.Arrowhead Pharmaceuticals’s quarterly revenue was down 86.4% compared to the same quarter last year. During the same period in the prior year, the business posted $2.75 EPS. As a group, sell-side analysts anticipate that Arrowhead Pharmaceuticals will post -2.98 earnings per share for the current year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.